Assertio and Garda Reach Agreement to Delay Acquisition Launch
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ASRT?
Source: Newsfilter
- Acquisition Agreement Delay: Assertio and Garda have mutually agreed to postpone the launch of the acquisition tender offer to May 14, 2026, which may affect short-term shareholder decisions and potentially diminish market confidence in the acquisition.
- Cash Acquisition Price: Under the amended merger agreement, Garda will acquire Assertio at $21.80 per share, totaling $153.2 million in cash, a price that may be perceived as insufficiently attractive in the current market environment.
- Convertible Senior Notes Offer Postponed: Assertio has also decided to delay the tender offer for all outstanding Convertible Senior Notes until May 14, 2026, which could influence investors' perceptions of the company's financial stability.
- Future Outlook Uncertainty: The delays in the acquisition and tender offers create uncertainty for Assertio's future development, potentially impacting its competitive position in the oncology market, especially at a critical time when investor attention is heightened.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASRT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASRT
Wall Street analysts forecast ASRT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 22.370
Low
35.00
Averages
40.00
High
45.00
Current: 22.370
Low
35.00
Averages
40.00
High
45.00
About ASRT
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Assertio and Garda Reach Agreement to Delay Acquisition Launch
- Acquisition Agreement Delay: Assertio and Garda have mutually agreed to postpone the launch of the acquisition tender offer to May 14, 2026, which may affect short-term shareholder decisions and potentially diminish market confidence in the acquisition.
- Cash Acquisition Price: Under the amended merger agreement, Garda will acquire Assertio at $21.80 per share, totaling $153.2 million in cash, a price that may be perceived as insufficiently attractive in the current market environment.
- Convertible Senior Notes Offer Postponed: Assertio has also decided to delay the tender offer for all outstanding Convertible Senior Notes until May 14, 2026, which could influence investors' perceptions of the company's financial stability.
- Future Outlook Uncertainty: The delays in the acquisition and tender offers create uncertainty for Assertio's future development, potentially impacting its competitive position in the oncology market, especially at a critical time when investor attention is heightened.
See More
Garda Therapeutics Raises Acquisition Offer to $21.80 per Share
- Increased Acquisition Offer: Garda Therapeutics has raised its all-cash tender offer for Assertio Holdings to $21.80 per share, valuing the company at approximately $153.2 million, which represents a 21.1% increase over the initial bid, indicating confidence in Assertio's future potential.
- Positive Stock Reaction: Following the announcement, Assertio's shares jumped 17% in early trading, reflecting a positive market response to the revised offer and enhancing investor confidence in the company's value.
- Amended Merger Agreement: The companies entered into an amended merger agreement on May 1 after a “window-shop” process, where Assertio engaged with multiple parties and received a superior proposal, prompting further negotiations with Garda to ensure the best outcome for shareholders.
- Expected Transaction Completion: Under the terms, Garda will acquire all outstanding shares at $21.80 each, with the deal expected to close in the second quarter of 2026, leading to Assertio's delisting from Nasdaq and marking a significant strategic shift for the company.
See More
ASSERTIO: GARDA TO PURCHASE ALL OUTSTANDING SHARES OF CO FOR $21.80 EACH IN CASH UNDER REVISED AGREEMENT TERMS
- Acquisition Announcement: GARDAT has announced its intention to acquire all outstanding shares of COFOR for $21.80 per share in cash.
- Terms of Agreement: The acquisition is being conducted under the terms of an amended agreement.
See More
ASSERTIO HOLDINGS INC: RAISES ALL-CASH TENDER OFFER TO $21.80 PER SHARE, TOTALING $153.2 MILLION
Company Announcement: Assertio Holdings has announced an all-cash tender offer for its shares.
Offer Details: The tender offer price is set at $21.80 per share, totaling approximately $153.2 million.
See More
ASSERTIO REVEALS REVISED MERGER AGREEMENT WITH GARDA THERAPEUTICS
Announcement of Agreement: Assertio Therapeutics has announced an amended and restated merger agreement with Garuda Therapeutics.
Details of the Merger: The agreement outlines the terms and conditions under which the merger will take place, aiming to enhance both companies' capabilities in the therapeutic market.
See More
Assertio Reaches Acquisition Agreement with Garda
- Acquisition Agreement Extended: Assertio and Garda have mutually agreed to extend the deadline for the tender offer to May 4, 2026, providing Assertio additional time to explore potentially superior bids, which could impact shareholder returns.
- Cash Acquisition Terms: Under the agreement, Garda will acquire Assertio at $18.00 per share, totaling $125.1 million in cash, reflecting Garda's commitment to Assertio while offering shareholders a clear value proposition.
- Window-Shop Provision: The agreement includes a 20-day
See More
Assertio and Garda Reach Agreement to Delay Acquisition Launch
- Acquisition Agreement Delay: Assertio and Garda have mutually agreed to postpone the launch of the acquisition tender offer to May 14, 2026, which may affect short-term shareholder decisions and potentially diminish market confidence in the acquisition.
- Cash Acquisition Price: Under the amended merger agreement, Garda will acquire Assertio at $21.80 per share, totaling $153.2 million in cash, a price that may be perceived as insufficiently attractive in the current market environment.
- Convertible Senior Notes Offer Postponed: Assertio has also decided to delay the tender offer for all outstanding Convertible Senior Notes until May 14, 2026, which could influence investors' perceptions of the company's financial stability.
- Future Outlook Uncertainty: The delays in the acquisition and tender offers create uncertainty for Assertio's future development, potentially impacting its competitive position in the oncology market, especially at a critical time when investor attention is heightened.
See More
Garda Therapeutics Raises Acquisition Offer to $21.80 per Share
- Increased Acquisition Offer: Garda Therapeutics has raised its all-cash tender offer for Assertio Holdings to $21.80 per share, valuing the company at approximately $153.2 million, which represents a 21.1% increase over the initial bid, indicating confidence in Assertio's future potential.
- Positive Stock Reaction: Following the announcement, Assertio's shares jumped 17% in early trading, reflecting a positive market response to the revised offer and enhancing investor confidence in the company's value.
- Amended Merger Agreement: The companies entered into an amended merger agreement on May 1 after a “window-shop” process, where Assertio engaged with multiple parties and received a superior proposal, prompting further negotiations with Garda to ensure the best outcome for shareholders.
- Expected Transaction Completion: Under the terms, Garda will acquire all outstanding shares at $21.80 each, with the deal expected to close in the second quarter of 2026, leading to Assertio's delisting from Nasdaq and marking a significant strategic shift for the company.
See More
ASSERTIO: GARDA TO PURCHASE ALL OUTSTANDING SHARES OF CO FOR $21.80 EACH IN CASH UNDER REVISED AGREEMENT TERMS
- Acquisition Announcement: GARDAT has announced its intention to acquire all outstanding shares of COFOR for $21.80 per share in cash.
- Terms of Agreement: The acquisition is being conducted under the terms of an amended agreement.
See More
ASSERTIO HOLDINGS INC: RAISES ALL-CASH TENDER OFFER TO $21.80 PER SHARE, TOTALING $153.2 MILLION
Company Announcement: Assertio Holdings has announced an all-cash tender offer for its shares.
Offer Details: The tender offer price is set at $21.80 per share, totaling approximately $153.2 million.
See More
ASSERTIO REVEALS REVISED MERGER AGREEMENT WITH GARDA THERAPEUTICS
Announcement of Agreement: Assertio Therapeutics has announced an amended and restated merger agreement with Garuda Therapeutics.
Details of the Merger: The agreement outlines the terms and conditions under which the merger will take place, aiming to enhance both companies' capabilities in the therapeutic market.
See More
Assertio Reaches Acquisition Agreement with Garda
- Acquisition Agreement Extended: Assertio and Garda have mutually agreed to extend the deadline for the tender offer to May 4, 2026, providing Assertio additional time to explore potentially superior bids, which could impact shareholder returns.
- Cash Acquisition Terms: Under the agreement, Garda will acquire Assertio at $18.00 per share, totaling $125.1 million in cash, reflecting Garda's commitment to Assertio while offering shareholders a clear value proposition.
- Window-Shop Provision: The agreement includes a 20-day
See More
